2cureX AB (OSTO:2CUREX) Cash-to-Debt : No Debt ⁽¹⁾ (As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is 2cureX AB Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. 2cureX AB's cash to debt ratio for the quarter that ended in Sep. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, 2cureX AB could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for 2cureX AB's Cash-to-Debt or its related term are showing as below:

OSTO:2CUREX' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 8 years, 2cureX AB's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

OSTO:2CUREX's Cash-to-Debt is ranked better than
99.8% of 1538 companies
in the Biotechnology industry
Industry Median: 6.485 vs OSTO:2CUREX: No Debt

2cureX AB Cash-to-Debt Historical Data

The historical data trend for 2cureX AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

2cureX AB Cash-to-Debt Chart

2cureX AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

2cureX AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of 2cureX AB's Cash-to-Debt

For the Biotechnology subindustry, 2cureX AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

2cureX AB's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 2cureX AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where 2cureX AB's Cash-to-Debt falls into.

2cureX AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

2cureX AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

2cureX AB had no debt ⁽¹⁾.

2cureX AB's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

2cureX AB had no debt ⁽¹⁾.

2cureX AB (OSTO:2CUREX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

2cureX AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of 2cureX AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

2cureX AB (OSTO:2CUREX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2cureX AB (OSTO:2CUREX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

2QE:Germany

Address

Fruebjergvej 3, Copenhagen, DNK, DK-2100

Website

https://www.2curex.com

2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.

2cureX AB (OSTO:2CUREX) Headlines

No Headlines

2cureX AB (OSTO:2CUREX) Cash-to-Debt : No Debt (1) (As of Sep. 2023)